var data={"title":"Methyldopa: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methyldopa: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6562?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methyldopa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methyldopa: Patient drug information&quot;</a> and <a href=\"topic.htm?path=methyldopa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Methyldopa: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195033\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Methyldopa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195081\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha<sub>2</sub>-Adrenergic Agonist;</li>\n      <li>\n        Antihypertensive</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195037\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypertension:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Initial: 250 mg 2 to 3 times daily; increase or decrease daily dose every 2 days based on response (maximum dose: 3,000 mg/day); usual dose range (ASH/ISH [Weber 2014]): 250 to 500 mg twice daily. <b>Note:</b> When administered with other antihypertensives other than thiazide diuretics, limit initial daily dose of methyldopa to 500 mg/day. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: 250 to 1,000 mg every 6 to 8 hours; maximum: 1,000 mg every 6 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195059\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=methyldopa-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Methyldopa: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypertension:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Initial: 10 mg/kg/day in 2 to 4 divided doses; increase or decrease daily dose every 2 days based on response; maximum dose: 65 mg/kg/day or 3,000 mg/day. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: 5 to 10 mg/kg/dose every 6 to 8 hours; maximum dose: 65 mg/kg/day or 3,000 mg/day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195038\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Initiate at the lower end of the dosage range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195039\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &gt;50 mL/minute: Administer every 8 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10 to 50 mL/minute: Administer every 8 to 12 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;10 mL/minute: Administer every 12 to 24 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent hemodialysis: Moderately dialyzable (up to 60% with a 6-hour session): Administer after hemodialysis on dialysis days (Yeh 1970).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis (PD): Administer every 12 to 24 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Continuous renal replacement therapy (CRRT): Administer every 8 to 12 hours. <b>Note:</b> Use of antihypertensives in patients requiring CRRT is generally not recommended since CRRT is typically employed when patient cannot tolerate intermittent hemodialysis due to hypotension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14477031\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use is contraindicated in patients with active hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195006\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/5 mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194989\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23610379\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral: 125 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195010\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 30 to 60 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer new dosage increases in the evening to minimize sedation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195009\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension: </b>Management of hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> According to the Eighth Joint National Committee (JNC 8) guidelines, methyldopa is <b>not</b> recommended for the initial treatment of hypertension (James 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195090\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Methyldopa may be confused with L-dopa, levodopa</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Methyldopa is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to high risk of CNS adverse effects and risk of bradycardia and orthostatic hypotension associated with central alpha blockers; not recommended as routine treatment for hypertension (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Methyldopa is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s (PQA), Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aldomet [Multiple international markets] may be confused with Aldactone brand name for spironolactone [US, Canada, multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194996\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, cardiac failure, exacerbation of angina pectoris, myocarditis, orthostatic hypotension, paradoxical pressor response (intravenous use), pericarditis, peripheral edema, prolonged carotid sinus syncope, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Bell&rsquo;s palsy, cerebrovascular insufficiency (symptoms), choreoathetosis, decreased mental acuity, depression, dizziness, drug fever, headache, nightmares, paresthesia, Parkinson&rsquo;s disease, sedation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea, decreased libido, gynecomastia, hyperprolactinemia, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, colitis, constipation, diarrhea, flatulence, glossalgia, melanoglossia, nausea, pancreatitis, sialadenitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Breast hypertrophy, impotence, lactation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bone marrow depression, eosinophilia, granulocytopenia, hemolytic anemia, leukopenia, positive ANA titer, positive direct Coombs test, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hepatic disease (hepatitis), jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, lupus-like syndrome, myalgia, positive rheumatoid factor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasal congestion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Positive LE cell preparation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195013\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to methyldopa or any component of the formulation; active hepatic disease (eg, acute hepatitis, active cirrhosis); hepatic disorders previously associated with use of methyldopa; concurrent use of MAO inhibitors</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194993\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Edema: May produce clinical edema or weight gain; discontinue if edema worsens or signs of heart failure arise. Mild edema may be controlled with the concomitant use of diuretic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic effects: Rare cases of reversible granulocytopenia and thrombocytopenia have been reported. May rarely produce hemolytic anemia; positive Coombs test occurs in 10% to 20% of patients usually occurring between 6 and 12 months of therapy; perform complete blood count (CBC) periodically. If methyldopa-induced Coombs-positive hemolytic anemia occurs during therapy, discontinue use and do not reinitiate; Coombs test may not revert back to normal for weeks to months following discontinuation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: May rarely produce hepatic disorders including fatal hepatic necrosis. Discontinue use and do not reinitiate if fever, abnormal liver function tests, or jaundice is present. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sedation: Usually transient, sedation may occur with initiation or whenever the dose is increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cerebrovascular disease: Patients with severe bilateral cerebrovascular disease have exhibited involuntary choreoathetotic movements (rare); discontinue use if these symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with history of hepatic disease or impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pheochromocytoma: Not recommended in patients with pheochromocytoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may respond to smaller doses. The active metabolites of methyldopa accumulate in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Surgical patients: Patients on methyldopa may need less anesthetic agents (Miller 1968; Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Injection: Do not use injectable if bisulfite allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tolerance: May occur usually between the second and third month of therapy; adding a diuretic or increasing the dosage of methyldopa frequently restores blood pressure control. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299698\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of COMT</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194998\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9635&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">COMT Inhibitors: May decrease the metabolism of COMT Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Methyldopa may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Methyldopa.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Methyldopa may enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Methyldopa.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Methyldopa. Management: Consider separating doses of these products by 2 or more hours to minimize this interaction; however, the success of this action appears limited.  Monitor for decreased therapeutic effects of methyldopa with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195001\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (injectable) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195016\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Methyldopa crosses the placenta and appears in cord blood. Available data show use during pregnancy does not cause fetal harm and improves fetal outcomes. Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for chronic hypertension during pregnancy is needed, methyldopa is one of the preferred agents. If an injectable agent is needed for the urgent control of acute hypertension in pregnancy, other agents are preferred (ACOG, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21190562\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Methyldopa is excreted in breast milk in concentrations &lt;1% of the weight-adjusted maternal dose (Jones 1978; White 1985). The manufacturer recommends that caution be exercised when  administering methyldopa to breast-feeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195018\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Dietary requirements for vitamin B<sub>12</sub> and folate may be increased with high doses of methyldopa.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195004\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure (standing and sitting/lying down), CBC, liver enzymes (periodically during the first 6 to 12 weeks or when unexplained fever occurs), Coombs test (direct) (may obtain prior to initiation and at 6 and 12 months); blood pressure monitor required during IV administration </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194992\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulation of central alpha-adrenergic receptors by a false neurotransmitter (alpha-methylnorepinephrine) that results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195012\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peak effect: Hypotensive: Oral, IV: Single-dose: Within 3 to 6 hours; Multiple-dose: 48 to 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral: Single-dose: 12 to 24 hours, Multiple-dose: 24 to 48 hours; IV: 10 to 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Incomplete due to presystemic gut metabolism (Skerjanec 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.23 L/kg (Myhre 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 10% to 15% (Myhre 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Intestinal and hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~42% (Skerjanec 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Neonates: 10 to 20 hours; Adults: 1.5 to 2 hours; End-stage renal disease: Prolonged (Myhre 1982) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: 2 to 4 hours (Myhre 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~70% as parent drug and metabolites); excretion complete within 36 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195015\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Methyldopate HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (5 mL): $48.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Methyldopa Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $37.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $67.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195019\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adopal (FI);</li>\n      <li>Aldin (TW);</li>\n      <li>Aldomet (AE, AR, AU, BD, BE, BF, BH, BJ, BR, CH, CI, CR, CY, DK, DO, EG, ES, ET, FR, GB, GH, GM, GN, GR, GT, HN, IL, IQ, IR, IT, JO, KE, KW, LB, LK, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, OM, PA, PE, PH, PK, PT, PY, QA, SA, SC, SD, SE, SG, SL, SN, SV, SY, TN, TZ, UG, UY, VE, VN, YE, ZM, ZW);</li>\n      <li>Aldomet Forte (ES);</li>\n      <li>Aldomet-Forte (HK);</li>\n      <li>Aldometil (AT);</li>\n      <li>Aldopa (PY);</li>\n      <li>Alfamed (LK);</li>\n      <li>Alfamet (TR);</li>\n      <li>Alphadopa (IN);</li>\n      <li>Bekanta (JP);</li>\n      <li>Domecin (JP);</li>\n      <li>Dopaflex (BD);</li>\n      <li>Dopagyt (IN);</li>\n      <li>Dopamed (TH);</li>\n      <li>Dopamet (HK, ID, PH, TR);</li>\n      <li>Dopanore (AE, JO, SA);</li>\n      <li>Doparine (PH);</li>\n      <li>Dopatab (ZW);</li>\n      <li>Dopatab M (HK);</li>\n      <li>Dopegyt (AE, BB, BD, BG, BH, BM, BS, BZ, CY, CZ, EG, GY, HU, IL, IQ, IR, JM, JO, KW, LB, LV, LY, MY, OM, PL, PR, QA, RO, RU, SA, SR, SY, TT, VN, YE);</li>\n      <li>Dopehit (UA);</li>\n      <li>Dopress (KR);</li>\n      <li>Emdopa (IN);</li>\n      <li>Fidopa (BD);</li>\n      <li>Hy-po-tone (ZA);</li>\n      <li>Hydopa (AU, HK);</li>\n      <li>Hypolag (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>Hypotens (ZW);</li>\n      <li>Matilda (TH);</li>\n      <li>Medopa (JP, TH);</li>\n      <li>Medoram (JO);</li>\n      <li>Mefpa (TH);</li>\n      <li>Methoplain (JP);</li>\n      <li>Metildopa (CL, HR);</li>\n      <li>Metpata (TH);</li>\n      <li>Normopress (ZA);</li>\n      <li>Pharmet (ZA);</li>\n      <li>Presinol (AT, DE);</li>\n      <li>Presinol 500 (DE);</li>\n      <li>Prodopa (NZ);</li>\n      <li>Rivapress (TW);</li>\n      <li>Sardopa (BD);</li>\n      <li>Sembrina (BF, BJ, CI, ET, FI, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Siamdopa (TH);</li>\n      <li>Stridopa (ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&rsquo; Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline.  <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones HM and Cummings AJ, &quot;A Study of the Transfer of Alpha-Methyldopa to the Human Foetus and Newborn Infant,&quot; <i>Br J Clin Pharmacol</i>, 1978, 6(5):432-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/728288/pubmed\" target=\"_blank\" id=\"728288\">728288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Methyldopa [prescribing information]. Durham, NC: Accord Healthcare Inc.; 2012</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, <i>Miller&rsquo;s Anesthesia</i>,  7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, Way WL, and Eger EI. The effects of alpha-methyldopa, reserpine, guanethidine, and iproniazid on minimum alveolar anesthetic requirement (MAC). <i>Anesthesiology</i>. 1968; 29(6):1153-1158.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/5726752/pubmed\" target=\"_blank\" id=\"5726752\">5726752</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myhre E, Rugstad HE, and Hansen T, &ldquo;Clinical Pharmacokinetics of Methyldopa,&rdquo; <i>ClinPharmacokinet</i>, 1982, 7(3):221-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/7047042 /pubmed\" target=\"_blank\" id=\"7047042 \">7047042 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newton DW, Fung EY, and Williams DA, &ldquo;Stability of Five Catecholamines and Terbutaline Sulfate in 5% Dextrose Injection in the Absence and Presence of Aminophylline,&rdquo; <i>Am J Hosp Pharm</i>, 1981, 38(9):1314-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/7282714/pubmed\" target=\"_blank\" id=\"7282714\">7282714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skerjanec A, Campbell NR, Robertson S, et al, &ldquo;Pharmacokinetics and Presystemic Gut Metabolism of Methyldopa in Healthy Human Subjects,&rdquo; <i>J Clin Pharmacol</i>, 1995, 35(3):275-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/7608316/pubmed\" target=\"_blank\" id=\"7608316\">7608316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the Management of Hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White WB, Andreoli JW, and Cohn RD, &quot;Alpha-Methyldopa Disposition in Mothers With Hypertension and in Their Breast-Fed Infants,&quot; <i>Clin Pharmacol Ther</i>, 1985, 37(4):387-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/3838502/pubmed\" target=\"_blank\" id=\"3838502\">3838502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yeh BK, Dayton PG, and Waters WC 3rd. Removal of alpha-methyldopa (aldomet) in man by dialysis. <i>Proc Soc Exp Biol Med</i>. 1970;135(3):840-843.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methyldopa-drug-information/abstract-text/5486722/pubmed\" target=\"_blank\" id=\"5486722\">5486722</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9635 Version 158.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F195033\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F195081\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F195037\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F195059\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F195038\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F195039\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14477031\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195006\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F194989\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F23610379\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F195010\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F195009\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F195090\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F194996\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195013\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F194993\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299698\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F194998\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F195001\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F195016\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21190562\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F195018\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F195004\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F194992\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F195012\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F195015\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F195019\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9635|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methyldopa-patient-drug-information\" class=\"drug drug_patient\">Methyldopa: Patient drug information</a></li><li><a href=\"topic.htm?path=methyldopa-pediatric-drug-information\" class=\"drug drug_pediatric\">Methyldopa: Pediatric drug information</a></li></ul></div></div>","javascript":null}